BROSSARD, Quebec, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a leader in early detection of critical health issues using advanced Artificial Intelligence (AI), announces that it intends to amend the terms of an aggregate amount of $590,000 of unsecured convertible debentures (each a “Debenture”) issued as part of a private placement of units initially announced on March 1, 2022, as follows:
DIAGNOS Announces Amendment to Convertible Debentures
Seeking Alpha / 1 hour from now 2 Views
Comments